Penumbra, Inc. PEN

Set alert

Price alert · PEN

All alert types
321.34 USD +2.39 +0.75%

At close · Nov 2

321.34 0.00 0.00%

After hours · Nov 2, 4:00 PM ET

Bid
321.21 × 40
Ask
321.38 × 40
318.87 Day range 321.57
221.26 52-week range 362.41
YTD
+3.35%
1 year
+41.33%
Open
320.00
Prev close
318.95
Mkt cap
12.67B
Vol
463.54K
Avg vol
346.00K
EPS
3.97
P/E
80.94
Div yield
0.00%
More statistics
Low
318.87
High
321.57
Forward P/E
52.68
Beta
0.69
Short ratio
5.55
Inst. own
89.31%
Dividend
0.00
Ex-div date
Earnings
Feb 24, 2027
50-d avg
320.50
200-d avg
327.49
1y target
362.54

YTD chart

Chart tools
Interval

Events in this range
  • Jan 20, 2026Downgrade: RBC Capital · Outperform → Sector Perform
  • Feb 25, 2026Earnings: 1.18; estimate 1.11; surprise 6.31%
  • Feb 26, 2026Rating: Evercore ISI Group · Outperform → Outperform
  • May 6, 2026Earnings: 0.82; estimate 1.04; surprise -21.15%
  • May 7, 2026Rating: Evercore ISI Group · Outperform → Outperform
  • May 7, 2026Rating: Citigroup · Neutral → Neutral
  • Jun 11, 2026Rating: RBC Capital · Sector Perform → Sector Perform
  • Jul 6, 2026Rating: Evercore ISI Group · Outperform → Outperform
  • Jul 30, 2026Earnings: 0.88; estimate 1.16; surprise -24.14%
  • Oct 29, 2026Earnings: 1.07; estimate 1.2; surprise -10.83%
Signals (25)
NameDateAgo
SMA: BullishNov 2, 202613 hours ago
SMA: BearishOct 30, 20263 days ago
MACD: Sell SignalOct 30, 20263 days ago
SMA: BullishOct 29, 20264 days ago
SMA: BearishOct 28, 20265 days ago
SMA: BullishOct 19, 20262 weeks ago
MACD: Buy SignalOct 9, 20263 weeks ago
MACD: Sell SignalOct 2, 20261 month ago
MACD: Buy SignalSep 24, 20261 month ago
SMA: BearishSep 8, 20261 month ago
SMA: BearishAug 27, 20262 months ago
MACD: Sell SignalAug 20, 20262 months ago
RSI: OverboughtAug 11, 20262 months ago
SMA: BullishJul 27, 20263 months ago
MACD: Buy SignalJun 25, 20264 months ago
MACD: Sell SignalJun 11, 20264 months ago
MACD: Buy SignalJun 9, 20264 months ago
MACD: Sell SignalMay 28, 20265 months ago
MACD: Buy SignalMay 18, 20265 months ago
MACD: Sell SignalApr 28, 20266 months ago
MACD: Buy SignalApr 14, 20266 months ago
SMA: BearishMar 10, 20267 months ago
MACD: Sell SignalFeb 3, 20269 months ago
MACD: Buy SignalJan 15, 20269 months ago
RSI: OverboughtJan 15, 20269 months ago

Key statistics

Market cap
12.67B
Enterprise value
12.11B
Trailing P/E
80.94
Forward P/E
52.68
PEG ratio
3.59
Price / sales
8.12
Price / book
8.00
EPS (TTM)
3.97
Beta
0.69
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
10.06%
Revenue (TTM)
1.56B
Revenue growth
15.60%
Free cash flow
166.09M
Total cash
673.61M
Total debt
209.39M
Return on equity
10.67%
Shares outstanding
39.41M
Short % of float
6.60%
50-day average
320.50
200-day average
327.49

Analyst view

Consensus: hold

Hold
Price target (mean) 362.54 +12.8% upside
Target (low)
320.00
Target (mean)
362.54
Target (high)
374.00
Ratings (0m) 17 3 buy · 14 hold · 0 sell
  • Strong buy1
  • Buy2
  • Hold14
  • Sell0
  • Strong sell0

Next earnings

Feb 24, 2027

Expected Feb 24, 2027. Consensus EPS estimate 1.47.

Earnings history

Financials — quick view

All financials
PEN Revenue — quarterly 410.14M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
PEN Net income — quarterly 42.28M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
PEN EPS — quarterly 1.07
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

PEN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 24, 2027Dec 30, 20261.44———
Oct 29, 2026Sep 30, 20261.201.07-0.13-10.83%
Jul 30, 2026Jun 30, 20261.160.88-0.28-24.14%
May 6, 2026Mar 31, 20261.040.82-0.22-21.15%
Feb 25, 2026Dec 31, 20251.111.18+0.07+6.31%
Nov 5, 2025Sep 30, 20250.9290.97+0.04+4.41%

Upgrades / downgrades

PEN analyst upgrades and downgrades
DateFirmActionFromTo
Jul 6, 2026Evercore ISI GroupmainOutperformOutperform
Jun 11, 2026RBC CapitalreitSector PerformSector Perform
May 7, 2026CitigroupmainNeutralNeutral
May 7, 2026Evercore ISI GroupmainOutperformOutperform
Feb 26, 2026Evercore ISI GroupmainOutperformOutperform
Jan 20, 2026RBC CapitaldownOutperformSector Perform

About Penumbra, Inc.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on PEN — it syncs with the Stock Master app.

Insider holders

PEN insider holders
InsiderRelationLatest transactionDateShares held
BOSE ARANIDirectorStock Award(Grant)Feb 12, 2026259,609
ELSESSER ADAMChief Executive OfficerStock GiftMay 18, 20260
GREWAL HARPREET SINGHDirectorSaleApr 1, 20268,719
KASSING DON WDirectorStock Award(Grant)Feb 13, 20259,909
LEEDS JANETDirectorStock Award(Grant)Feb 12, 20266,639
NARAYAN SHRUTHIPresidentStock Award(Grant)Aug 16, 202633,880

Institution ownership

PEN institution ownership
Holder% heldSharesValueReported
Blackrock Inc.10.90%4,297,5551.38BJun 29, 2026
HBK Investments L P4.66%1,838,508590.80MJun 29, 2026
Vanguard Capital Management LLC4.34%1,709,877549.47MJun 29, 2026
Vanguard Portfolio Management LLC4.23%1,667,276535.78MJun 29, 2026
State Street Corporation3.15%1,243,258399.52MJun 29, 2026
ExodusPoint Capital Management, LP2.77%1,090,430350.41MJun 29, 2026

Fund ownership

PEN fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Mid-Cap ETF3.56%1,403,042450.87MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.01%1,186,100381.15MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.17%856,690275.30MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund1.25%494,387158.87MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.14%450,774144.86MJun 29, 2026
SmallCap World Fund Inc1.05%412,644132.60MSep 29, 2026